Arvinas (ARVN) Short term Debt (2017 - 2023)

Arvinas' (ARVN) quarterly Short term Debt came in at $200000.0 in Q3 2023, up 100.0% quarter-over-quarter from $100000.0 in Q2 2023.

Arvinas (ARVN) Short term Debt (2017 - 2023) Analysis & Trends

Arvinas' Short term Debt history runs 4 years deep, the most recent figure standing at $200000.0 for Q3 2023.

On a quarterly basis, Short term Debt changed N/A year-over-year to $200000.0 in Q3 2023; TTM through Sep 2023 was $200000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $154461.0, down 3.02% from the prior year.
Short term Debt climbed to $200000.0 in Q3 2023 per ARVN's latest filing, from $100000.0 in the prior quarter.
Across five years, Short term Debt topped out at $200000.0 in Q3 2023 and bottomed at $71499.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Arvinas	512.64 Mn	-102.26 Mn	-

Download Data